Dear Doctor Letter (Rote-Hand-Brief) on Victrelis (boceprevir): Drug interactions with ritonavir-boosted HIV protease inhibitors
2012.02.24
Active substance: boceprevir
In co-ordination with the European Medicines Agency (EMA) the pharmaceutical entrepreneur is circulating information on new findings on drug interactions between boceprevir, a recently licensed oral inhibitor of the hepatitis C virus (HCV)-NS3/4A protease, and ritonavir-boosted HIV protease inhibitors.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN